Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-10T06:58:00.008Z Has data issue: false hasContentIssue false
  • English
  • Français

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

Published online by Cambridge University Press:  07 June 2007

Robert Kerwin ,
Bruno Millet ,
Erik Herman ,
Csaba M. Banki ,
Henrik Lublin ,
Miranda Pans ,
Linda Hanssens ,
Gilbert L'Italien ,
Robert D. McQuade  and
Jean-Noël Beuzen
Robert Kerwin
Affiliation:
institute of Psychiatry, London, England
Bruno Millet
Affiliation:
Centre Hospitalier Guillaume Regnier, Rennes, France
Erik Herman
Affiliation:
Psychiatry Department Charles University, Prague, Czech Republic
Csaba M. Banki
Affiliation:
Regional Psychiatric Hospital, Nagykallo, Hungary
Henrik Lublin
Affiliation:
Psychiatric Centre Glostrup, Glostrup, Denmark
Miranda Pans
Affiliation:
Bristol-Myers Squibb Company, Braine-l'Alleud, Belgium
Linda Hanssens*
Affiliation:
Bristol-Myers Squibb Company, Braine-l'Alleud, Belgium
Gilbert L'Italien
Affiliation:
Bristol-Myers Squibb Company, Wallingford, CT, USA
Robert D. McQuade
Affiliation:
Otsuka Pharmaceutical Development and Commercialization, inc., Princeton, NJ, USA
Jean-Noël Beuzen
Affiliation:
Bristol-Myers Squibb Company, Paris, France
*
∗Corresponding author. Tel.: +32 2 352 7152; fax: +32 2 352 7887. E-mail address: linda.hanssens@bms.com (L. Hanssens).
Get access

Abstract

Background

Naturalistic effectiveness trials of atypical antipsychotics are needed to provide broader information on efficacy, safety, and tolerability in patients with schizophrenia treated in a community practice setting.

Method

in this 26-week, open-label, multicentre study, patients with schizophrenia requiring a switch in antipsychotic medication because current medication was not well tolerated and/or clinical symptoms were not well controlled were randomized to receive aripiprazole or an atypical antipsychotic standard of care (SOC) treatment (i.e., olanzapine, quetiapine, or risperidone based on the investigator's judgment of the optimal treatment for the individual patient and the patient's prior response to antipsychotic medication). The primary objective was to compare the effectiveness of a 26-week treatment of aripiprazole versus SOC, as measured by the investigator Assessment Questionnaire (IAQ) total score at Week 26 last observation carried forward (LOCF) (primary endpoint), a validated measure that monitors relief or worsening of 10 key symptoms associated with the psychopathology of schizophrenia and side effects of antipsychotic treatment. Secondary objectives were to further assess effectiveness using the Clinical Global Impression – Global Improvement (CGI-I) and Clinical Global Impression – Severity of Illness scale, to assess time to treatment discontinuation, patient preference of medication, quality of life, and the tolerability of aripiprazole compared with SOC.

Results

Aripiprazole treatment (n = 268) resulted in significantly better effectiveness than SOC treatment (n = 254; P < 0.001; Week 26 LOCF) as evidenced by the IAQ total score beginning at Week 4 (the first assessment point) and sustained through Week 26. A similar relationship was demonstrated among patients who completed the study (observed cases analysis); aripiprazole was associated with significantly better effectiveness at all time points with a greater differential effect from SOC over time. Patients treated with aripiprazole also demonstrated significantly greater improvements on the CGI-I scale (responder rate, P = 0.009 at Week 26 LOCF), as well as on quality of life (Quality of Life scale total score; P < 0.001 at Week 26). Furthermore, a significantly higher proportion of patients receiving aripiprazole rated their study medication as “much better” on the Preference of Medication Questionnaire (POM) scale than their pre-study medication compared with SOC patients (P < 0.001; Week 26). Time to treatment discontinuation and rates of discontinuation due to adverse events were similar in both treatment groups. The incidence of patients with one or more extrapyramidal symptom (e.g., akathisia, dystonia, parkinsonian events, and residual events) was higher in patients receiving aripiprazole compared with patients treated with SOC (13.5% vs. 5.6%); however, a higher proportion of patients in the SOC-treated group had clinically significant weight gain (21.2% vs. 7.3% for aripiprazole) and potentially clinically relevant elevated fasting levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, and serum prolactin compared with patients receiving aripiprazole.

Conclusions

Aripiprazole is an effective atypical antipsychotic for the treatment of schizophrenia, demonstrating better effectiveness than SOC agents used in this study in patients for whom a switch in antipsychotic medication was warranted.

Keywords

AripiprazoleStandard of careSchizophrenia
Type
Original article
Information
European Psychiatry , Volume 22 , Issue 7 , October 2007 , pp. 433 - 443
Copyright
Copyright © Elsevier Masson SAS 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abraham, G., Paing, W.W., Kaminski, J., Joseph, A., Kohegyi, E., Josiassen, R.C.Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003;160:1618–1620.CrossRefGoogle Scholar
Awad, A.G., Voruganti, L.N.P.Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877–893.CrossRefGoogle ScholarPubMed
Bobes, J., Canas, F., Rejas, J., Mackell, J.Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1287–1297.CrossRefGoogle ScholarPubMed
Bombardier, C., Maetzel, A.Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?. ann Rheum Dis 58Suppl 11999 I82–I85.CrossRefGoogle ScholarPubMed
Dossenbach, M., Hodge, A., anders, M., Molnar, B., Peciukaitiene, D., Krupka-Matuszczyk, I.et al.Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. int J Neuropsychopharmacol 2005;8:195–201.CrossRefGoogle ScholarPubMed
Dubisar, B.M., Stoner, S.C., Reynolds, J., Khan, R., Ramlatchman, L.Adverse effects of atypical antipsychotic agents and their effects on quality of life. Pharmacotherapy 2004;24:843–847.CrossRefGoogle ScholarPubMed
Eaddy, M., Grogg, A., Locklear, J.Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27:263–272.CrossRefGoogle Scholar
EuroQol Group, EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199–208.Google Scholar
Gilmer, T.P., Dolder, C.R., Lacro, J.P., Folsom, D.P., Lindamer, L., Garcia, P.et al.Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692–699.CrossRefGoogle ScholarPubMed
Guy, W.ECDEU assessment manual for psychopharmacology – revised. Rockville, MD: US Department of Health Services; 1976.Google Scholar
Haddad, P.M., Wieck, A.antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291–2314.CrossRefGoogle ScholarPubMed
Hamann, J., Cohen, R., Leucht, S., Busch, R., Kissling, W.Do patients with schizophrenia wish to be involved in decisions about their medical treatment?. Am J Psychiatry 2005;162:2382–2384.CrossRefGoogle ScholarPubMed
Heinrichs, D.W., Hanlon, T.E., Carpenter, W.T. Jr.The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388–398.CrossRefGoogle ScholarPubMed
Jaffe, A.B., Levine, J.Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J Clin Psychiatry 2003;64:3–6.Google Scholar
Kapur, S., Remington, G.Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. annu Rev Med 2001;52:503–517.CrossRefGoogle ScholarPubMed
Kolotkin, R.L., Crosby, R.D., Kosloski, K.D., Williams, G.R.Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102–111.CrossRefGoogle ScholarPubMed
Lambert, M., Conus, P., Eide, P., Mass, R., Karow, A., Moritz, S.et al.Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415–422.CrossRefGoogle ScholarPubMed
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O.et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223.CrossRefGoogle ScholarPubMed
Lindstrom, E., Bingefors, K.Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106–124.CrossRefGoogle ScholarPubMed
Marder, S.R.Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 2005;111:43–46.CrossRefGoogle Scholar
Miyamoto, S., Duncan, G.E., Marx, C.E., Lieberman, J.A.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79–104.CrossRefGoogle ScholarPubMed
NCEP, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.Google Scholar
Newcomer, J.W.Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19:1–93.CrossRefGoogle ScholarPubMed
NICE, Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London, UK: National institute for Clinical Excellence; 2002 Report No.: Technology Appraisal Guidance No. 43.Google Scholar
Osby, U., Correia, N., Brandt, L., Ekbom, A., Sparen, P.Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000;321:483–484.CrossRefGoogle ScholarPubMed
Perkins, D.O.Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–1128.CrossRefGoogle ScholarPubMed
Peuskens, J.Clinical effectiveness in adults with chronic schizophrenia. Eur Neuropsychopharmacol 2004;14(Suppl 4):S453–S459.CrossRefGoogle ScholarPubMed
Pigott, T.A., Carson, W.H., Saha, A.R., Torbeyns, A.F., Stock, E.G., ingenito, G.G.Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048–1056.CrossRefGoogle ScholarPubMed
Ritsner, M., Perelroyzen, G., Ilan, H., Gibel, A.Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24:245–254.CrossRefGoogle ScholarPubMed
Saari, K., Koponen, H., Laitinen, J., Jokelainen, J., Lauren, L., isohanni, M.et al.Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004;65:547–550.CrossRefGoogle ScholarPubMed
Sebastian, C.S., Glazer, W., Buckley, P.F.Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 2004;11:329–342.CrossRefGoogle ScholarPubMed
Stein, E.The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler Suppl 2002;2:19–23discussion -5.CrossRefGoogle ScholarPubMed
Tandon, R., Devellis, R.F., Han, J., Li, H., Frangou, S., Dursun, S.et al.Validation of the investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005;136:211–221.CrossRefGoogle ScholarPubMed
Tandon, R., Marcus, R.N., Stock, E.G., Riera, L.C., Kostic, D., Pans, M.et al.A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77–89.CrossRefGoogle Scholar
Wang, P.S., Walker, A.M., Tsuang, M.T., Orav, E.J., Glynn, R.J., Levin, R.et al.Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002;59:1147–1154.CrossRefGoogle ScholarPubMed
Wilson, P.W., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B.Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847.CrossRefGoogle ScholarPubMed
Wirshing, D.A.Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl 18):13–26.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.